Abstract: Disclosed herein are methods for treating or prophylactically treating age-related cognitive decline associated with dementia by administering recombinant viral vectors designed to deliver TERT and/or KL (Klotho) genes to the patient. The TERT and/or KL genes are packaged within one or more AAV viral vectors and administered to the CNS of the patient via intranasal and/or intrathecal injection. The therapy can provide improvements in cognitive function as evidenced by improved Folstein/MMSE scores over time.

Abstract: Gene therapy vectors can include a cytomegalovirus vector encoding one or more therapeutic donor genes. These vectors can be used in exemplary gene therapy methods for maintaining or improving one or more aspects of a recipient's physiological wellness and/or longevity. The recombinant viral vector can be administered or received intranasally or as an injectable therapeutic (singly or as a serial set of administrations) to beneficially cause one or more of the following salubrious effects in the patient: increased longevity, inhibited muscle degeneration, increases mitochondrial health, prevention of age-related hair loss, and/or increased blood glucose tolerance.

Abstract: Disclosed are methods for gene therapy by administration of genetically modified viral vectors. Gene therapy vectors can include a cytomegalovirus vector encoding one or more therapeutic donor genes such as human telomerase reverse transcriptase (hTERT). These vectors can be used in exemplary gene therapy methods for maintaining or improving one or more aspects of a recipient's physiological wellness and/or longevity.

Abstract: Disclosed are methods for reducing effects of aging in a subject by administering a therapeutically effective amount of a human Telomerase Reverse Transcriptase (hTERT) gene in combination with a Follistatin-344 gene. The subject may be a human. The methods can beneficially increase telomere length in the treated subject.

Abstract: This invention relates to the treatment of age-related disorders with a combination of the hTERT gene and the Follistatin gene in a delivery system such as in an adeno-associated viral vector. The Follistatin gene is expected to promote the division of stem cells that will regenerate the organism and the hTERT will prevent their depletion.

Abstract: A novel method for gene therapy using intranasal administration of genetically modified viral vectors. Target genes for therapeutic administration to a human patient, for many purposes such as production of telomerase in a patient's body, are selected and transfected into a bacterial cell. Viral transduction is used to infect a human-administrable virus with the target genes in the bacterial cell. A solution containing a therapeutic amount of transfected viral agents is intranasally administered the solution into a human patient.